3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
2
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gastrointestinal
1
Conditions
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Pancreatic Neoplasms
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
46
Cisplatin
31
Carboplatin
20
Cetuximab
16
Nivolumab
15
Paclitaxel
14
Radiotherapy, Intensity-Modulated
12
Radiotherapy
10
Docetaxel
10
Fluorouracil
9
Platinum
8
durvalumab
7
Taxes
7
1,2-diaminocyclohexaneplatinum II citrate
7
Radiation
6
tislelizumab
5
Magnetic Resonance Spectroscopy
5
Albumin-Bound Paclitaxel
5
cemiplimab
4
avelumab
4
Specimen Handling
4
Radiosurgery
4
Drug Therapy
4
Biopsy
4
130-nm albumin-bound paclitaxel
4
tremelimumab
3
palbociclib
3
olaparib
3
dostarlimab
3
atezolizumab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Squamous Cell Carcinoma of Head and Neck
×
tisotumab vedotin
×
Clear all
NCT03485209
2026-04-20
innovaTV 207
Seagen Inc.
Phase 2
Active not recruiting
350 enrolled